Analysis of p53 and mdm2 proteins in malignant fibrous histiocytoma in absence of gene alteration: Prognostic significance

Virchows Archiv

Volumn 435, Issue 6, 1999, Pages 596-605

  Molina, Pilar ^a   Pellín, Antonio ^a   Navarro, Samuel ^a   Boix, Javier ^a   Carda, Carmen ^a   Llombart Bosch, Antonio ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Malignant fibrous histiocytoma; Mdm2; p53; Prognosis and immunohistochemistry

Indexed keywords

PARAFFIN; PROTEIN MDM2; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER STATISTICS; CANCER SURVIVAL; CLINICAL ARTICLE; FROZEN SECTION; GENE DUPLICATION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALIGNANT FIBROUS HISTIOCYTOMA; MOUSE; NONHUMAN; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SINGLE STRAND CONFORMATION POLYMORPHISM; SOUTHERN BLOTTING; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

EID: 0032731825     PISSN: 09456317     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004280050446     Document Type: Article

References (71)

1. 1. Andreassen A, Oyjord T, Hoving E, Holm R, Florenes VA, Nesland JM, Myklebost O, Hoie J, Bruland OS, Borresen AL, Fodstad O (1993) p53 abnormalities in different subtypes of human sarcomas. Cancer Res 53:468-471
2. 2. Chen J, Marechal V, Levine AJ (1993) Mapping of the p53 and mdm2 interaction domains. Mol Cell Biol 13:4107-4114
3. 3. Cho Y, Gorina S, Jeffrey PD (1994) Pavietich crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265:346-355
4. 4. Cordon-Cardo C, Latres E, Drobnjak M, Oliva MR, Pollack D, Woodruff JM, Marechal V, Chen J, Brennan MF, Levine AJ (1994) Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 54:794-799
5. 5. Dazard JE, Augias D, Neel H, Mils V, Marechal V, Basset-Séguin N, Piette J (1997) MDM2 protein is expressed in different layers of normal human skin. Oncogene 14:1123-1128
6. 6. Diller L, Kassel J, Nelson CE, Gryka MA, Litwak G, Gebhardt M, Bressac B, Ozturk M, Baker SJ, Vogelstein B, Friend SH (1990) p53 function as a cell cycle control protein in osteosarcomas. Mol Cell Biol 10:5772-5781
7. 7. Drobnjak M, Latres E, Pollack D, Karpeh M, Dudas M, Woodruff JM, Brennan MF, Cordon-Cardo C (1994) Prognostic implications of p53 nuclear overexpression and high proliferation index of Ki-67 in adult soft-tissue sarcomas. J Natl Cancer Inst 86:549-554
8. 8. Enzinger FM, Weiss SW (1995) Malignant fibrohistiocytic tumors. Mosby, St. Louis, pp 351-380
9. 9. Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ (1988) Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered halflife. Mol Cell Biol 8:531-539
10. 10. Florenes VA, Maelandsmo GM, Forus A, Andreassen A, Myklebost O, Fodstad O (1994) MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status. J Natl Cancer Inst 86:1297-1335
11. 11. Forus A, Florenes VA, Maelandsmo GM, Meltzer PS, Fodstad O, Myklebost O (1993) Mapping of amplification units in the q13-14 region of chromosome 12 in human sarcomas: some amplica do not include MDM2. Cell Growth Differ 4:1065-1070
12. 12. Gorgoulis VG, Zoumpourlis V, Rassidakis GZ, Karameris A, Rassidakis AN, Spandidos DA, Kittas C (1996) A molecular and immunohistochemical study of the MDM2 protein isoforms and p53 gene product in bronchogenic carcinoma. J Pathol 180:129-137
13. 13. Günther T, Schneider-Stock R, Rys J, Niezabitowski A, Roessner A (1997) p53 gene mutations and expression of p53 and mdm2 proteins in invasive breast carcinoma. J Cancer Res Clin Oncol 123:388-394
14. 14. Harris CC, Hollstein M (1993) Clinical implications of the p53 tumor-suppressor gene. New Engl J Med 329:1318-1327
15. 15. Higashiyama M, Doi O, Kodama K, Yokouchi H, Kasugai T, Ishiguro S, Takami K, Nishisho I (1997) MDM2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation. Br J Cancer 75:1302-1308
16. 16. Hollstein M, Rice K, Greenblatt MS, Soussi T, Fuchs R, Sorlie T, Hovig E, Smith-Sorensen B, Montesano R, Harris CC (1994) Database of p53 gene somatic mutations in human tumours and cell lines. Nucleic Acids Res 22:3547-3551
17. 17. Hupp TR, Meek DW, Midgley CA, Lane DP (1992) Regulation of the specific DNA binding function of p53. Cell 71:875-886
18. 18. Jones SN, Roe AE, Donehower LA, Bradley A (1995) Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378:206-208
19. 19. Juven T, Barak Y, Zauberman A, George DL, Oren M (1993) Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. Oncogene 8:3411-3416
20. 20. Kawai A, Noguchi M, Beppu Y, Yokoyama R, Mukai K, Hirohashi S, Inoue H, Fukuma H (1994) Nuclear immunoreaction of p53 protein in soft tissue sarcomas. A possible prognostic factor. Cancer 73:2499-2505
21. 21. Keleti J, Quezado MM, Abaza MM, Raffeld M, Tsokos M (1996) The MDM2 oncoprotein is overexpressed in rhabdomyosarcoma cell lines and stabilizes wild-type p53 protein. Am J Pathol 149:143-151
22. 22. Kern SE, Pietenpol JA, Thiagalingam S, Seymour A, Kinzler KW, Vogelstein B (1991) Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 252:1708-1711
23. 23. Korkolopoulou P, Christodoulou P, Kouzelis K, Hadjiyannakis M, Priftis A, Stamoulis G, Seretis A, Thomas-Tsagli E (1997) MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor. Br J Cancer 75:1269-1278
24. 24. Kovar H, Auinger A, Jug G, Aryee D, Zoubek A, Salzer-Kuntschik M, Gadner H (1993) Narrow spectrum of infrequent p53 mutations and absence of MDM2 amplification in Ewing tumours. Oncogene 8:2683-2690
25. 25. Ladanyi M, Cha C, Lewis R, Jhanvar SC, Huvos AG, Healey JH (1993) MDM2 gene amplification in metastatic osteosarcoma. Cancer Res 53:16-18
26. 26. Landers JE, Haines DS, Strauss JF, George DL (1994) Enhanced translation: a novel mechanism of mdm2 oncogene overexpression identified in human tumor cells. Oncogene 9:2745-2750
27. 27. Lane DP, Crawford LV (1979) T antigen is bound to a host protein in SV40-transformed cells. Nature 278:261-263
28. 28. Larramendy ML, Tarkkanen M, Blomqvist C, Virolainen M, Wiklund T, Asko-Seljavaara S, Elomaa I, Knuutila S (1997) Comparative genomic hybridization of malignant fibrous histiocytoma reveals a novel prognostic marker. Am J Pathol 151:1153-1161
29. 29. Latres E, Drobnjak M, Pollack D, Oliva MR, Ramos M, Karpeh M, Wooddruff JM, Cordon-Cardo C (1994) Chromosome 17 abnormalities and TP53 mutations in adult soft tissue sarcomas. Am J Pathol 145:345-355
30. 30. Le Doussal V, Coindre JM, Leroux A, Hacene K, Terrier P, Bui NB, Bonichon F, Collin F, Mandard AM, Contesso G (1996) Prognostic factors for patients with localized primary malignant fibrous histiocytoma: a multicenter study of 216 patients with multivariate analysis. Cancer 77:1823-1830
31. 31. Leach FS, Tokino T, Meltzer P, Burrell M, Oliner JD, Smith S, Hill DE, Sidransky D, Kinzler KW, Vogelstein B (1993) P53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 15:2231-2234
32. 32. Levine AJ, Momand J, Finlay CA (1991) The p53 tumour suppressor gene. Nature 351:453-456
33. 33. Lianes P, Orlow I, Zhang Z, Oliva MR, Sarkis AS, Reuter VE, Cordon-Cardo C (1994) Altered patterns of MDM2 and TP53 expression in human bladder cancer. J Natl Cancer Inst 86:1325-1330
34. 34. Livingtone LR, White A, Sprouse J, Livanos E, Jacks T, Tisty TD (1979) Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 17:923-935
35. 35. Llombart-Bosch A, Carda C, Boix J, Pellin A, Peydro-Olaya A (1988) Value of nude mice xenografts in the expression of cell heterogeneity of human sarcomas of bone and soft tissue. Pathol Res Pract 183:683-692
36. 36. Lonardo F, Ueda T, Huvos AG, Healey J, Ladanyi M (1997) p53 and MDM2 alterations in osteosarcomas. Cancer 79: 1541-1547
37. 37. Marchetti A, Buttitta F, Pellegrini S, Merlo G, Chella A, Angeletti CA, Bevilacqua G (1995) mdm2 Gene amplification and overexpression in non-small cell lung carcinomas with accumulation of the p53 protein in the absence of p53 gene mutations. Diagn Mol Pathol 4:93-97
38. 38. Mayo LD, Berberich SJ (1996) Wild-type p53 protein is unable to activate the mdm-2 gene during F9 cell differentiation. Oncogene 13:2315
39. 39. Midgley CA, Lane DP (1997) p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene 15:1179-1189
40. 40. Miller CW, Aslo A, Won A, Tan M, Lampkin B, Koeffler HP (1996) Alterations of the p53, Rb and MDM2 genes in osteosarcomas. J Cancer Res Clin Oncol 122:559-565
41. 41. Mitsudomi T, Steinberg SM, Nau MM, Carbone D, D'Amico D, Bodner S, Oie HK, Linnoila RI, Mulshine JL, Minna JD, Gazdar AF (1992) p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene 7:171-180
42. 42. Momand J, Zambetti GP, Olson DC, George D, Levine AJ (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237-1245
43. 43. Montes de Oca Luna R, Tabor AD, Eberspaecher H, Hulboy D, Worth LL, Colman MS, Finlay CA, Lozano G (1996) The organization and expression of the mdm2 gene. Genomics 33:352-357
44. 44. Nakayama T, Toguchida J, Wadayama B, Kanoe H, Kotoura Y, Sasaki M (1995) MDM2 gene amplification in bone and soft-tissue tumors: association with tumor progression in differentiated adipose-tissue tumors. Int J Cancer (Pred Oncol) 64:342-346
45. 45. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B (1992) Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358:80-86
46. 46. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B (1993) Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362:857-860
47. 47. Olson DC, Marechal V, Momand J, Chen J, Romocki C, Levine AJ (1993) Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes. Oncogene 8:2353-2360
48. 48. Oren M, Maltzman W, Levine AJ (1981) Post-translational regulation of the 54K cellular tumor antigen in normal and transformed cells. Mol Cell Biol 1:101-110
49. 49. Patterson H, Gill S, Fisher C, Law MG, Jayatilake H, Fletcher CDM, Thomas M, Grimer R, Gusterson BA, Cooper CS (1994) Abnormalities of the p53 MDM2 and DCC genes in human leiomyosarcomas. Br J Cancer 69:1052-1058
50. 50. Pellín A, Boix-Ferrero J, Carpio D, López-Terrada D, Carda C, Navarro S, Peydró-Olaya A, Triche TJ, Llombart-Bosch A (1997) Molecular alterations of the RB1, TP53 and MDM2 genes in primary and xenografted human osteosarcomas. Diagn Mol Pathol 6:333-341
51. 51. Pezzi CM, Rawlings MS, Jr, Esgro JJ, Pollock RE, Romsdahl MM (1992) Prognostic factors in 227 patients with malignant fibrous histiocytoma. Cancer 69:2098-2103
52. 52. Piette J, Neel H, Marechal V (1997) Mdm2: keeping p53 under control. Oncogene 15:1001-1010
53. 53. Pollock RE, Lang A, El-Naggar AK, Radinsky R, Hung MC (1997) Enhanced MDM2 oncoprotein expression in soft tissue sarcoma: several possible regulatory mechanisms. Sarcoma 1:23-29
54. 54. Pritchard DJ, Reiman HM, Turcotte RE, Ilstrup DM (1993) Malignant fibrous histiocytoma of the soft tissue of the trunk and extremities. Clin Orthop 289:58-65
55. 55. Reid AH, Tsai MM, Venzon DJ, Wright CF, Lack EE, O'Leary TJM (1996) DM2 amplification, P53 mutation, and accumulation of the P53 gene product in malignant fibrous histiocytoma. Diagn Mol Pathol 5:65-73
56. 56. Rooser B, Willen H, Gustafson P, Alvegard TA, Rydholm A (1991) Malignant fibrous histiocytoma of soft tissue. A population-based epidemiologic and prognostic study of 137 patients. Cancer 67:499-505
57. 57. Sambrook J, Fritsch EF, Maniatis T (1989) Molecular cloning. A laboratory manual. Cold Spring Harbor Laboratory, New York
58. 58. Sarnow P, Ho YS, Williams J, Levine AJ (1982) Adenovirus E1b-58Kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 Kd cellular protein in transformed cells. Cell 28:387-394
59. 59. Schlott T, Reimer S, Jahns A, Ohlenbusch A, Ruschenburg I, Nagel H, Droese M (1997) Point mutations and nucleotide insertions in the MDM2 zinc finger structure of human tumours. J Pathol 182:54-61
60. 60. Shinjo K (1994) Analysis of prognostic factors and chemotherapy of malignant fibrous histiocytoma of soft tissue: a preliminary report. Jpn J Clin Oncol 24:154-159
61. 61. Sigalas I, Calvert AH, Anderson JJ, Neal DE, Lunec J (1996) Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nat Med 2:912-991
62. 62. Soini Y, Vahakangas K, Nuorva K, Kamel D, Lane DP, Paakko P (1992) p53 immunohistochemistry in malignant fibrous histiocytoma and other mesenchymal tumours. J Pathol 168:29-33
63. 63. Taubert H, Wurl P, Meye A, Berger D, Thamm B, Neumann K, Hinze R, Schmidt H, Rath FW (1995) Molecular and immunohistochemical p53 status in liposarcoma and malignant fibrous histiocytoma: identification of seven new mutations for soft tissue sarcomas. Cancer 76:1187-1196
64. 64. Toguchida J, Yamaguchi T, Ritchie B, Beauchamp RL, Dayton SH, Herrera GE, Yamamuro T, Kotoura Y, Sasaki MS, Little JB, et al. (1992) Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. Cancer Res 52:6194-6199
65. 65. Vogelstein B (1990) Cancer. A deadly inheritance. Nature 348:681-682
66. 66. Wadayama B, Toguchida J, Yamaguchi T, Sasaki MS, Kotoura Y, Yamamuro T (1993) p53 expression and its relationship to DNA alterations in bone and soft tissue sarcomas. Br J Cancer 68:1134-1139
67. 67. Weiss SW, Ezinger FM (1978) Malignant fibrous histiocytoma. An analysis of 200 cases. Cancer 41:2250-2266
68. 68. Wu X, Bayle JH, Olson D, Levine AJ (1993) The p53-mdm-2 autoregulatory feedback loop. Genes Dev 7:1126-1132
69. 69. Würl P, Meye A, Berger D, Bache M, Lautenschläger C, Schmidt H, Kalthoff H, Rath FW, Taubert H (1997) Prognostic relevance of C-terminal detection is enhanced by p53 positivity in soft tissue sarcomas. Diagn Mol Pathol 6:249-254
70. 70. Yang P, Hirose T, Hasegawa T, Seki K, Sano T, Hizawa K (1995) Prognostic implication of the p53 protein and Ki-67 antigen immunohistochemistry in malignant fibrous histiocytoma. Cancer 76:618-625
71. 71. Zagars GK, Mullen JR, Pollack A (1996) Malignant fibrous histiocytoma: outcome and prognostic factors following conservation surgery and radiotherapy. Int J Radiat Oncol Biol Phys 34:983-994